# Curriculum della attività scientifica della Prof. Paola Fossa

**Istruzione**
**1988-1991**: dottore di Ricerca in Scienze Farmaceutiche, Università degli Studi di Genova
**1988**: laurea in Farmacia, Università degli Studi di Genova
**1987**: abilitazione all'esercizio della Professione di Farmacista
**1987**: laurea in Chimica e Tecnologia Farmaceutiche, Università degli Studi di Genova

**Attività professionale**
**31/12/2022- ad oggi:** professore di I fascia nel settore concorsuale 03/D1 Chimica e Tecnologie Farmaceutiche, Tossicologiche e Nutraceutico-Alimentari, SSD CHIM08, Università degli Studi di Genova
**01/11/2005- 30/12/2021:** professore di II fascia nel settore concorsuale 03/D1 Chimica e Tecnologie Farmaceutiche, Tossicologiche e Nutraceutico-Alimentari, SSD CHIM08, Università degli Studi di Genova
**01/11/1994:** ricercatore nel settore concorsuale 03/D1 Chimica e Tecnologie Farmaceutiche, Tossicologiche e Nutraceutico-Alimentari, SSD CHIM08 (ex C07X- Farmaceutico), Università degli Studi di Genova.
**02/11/1991-31/10/1994:** chimico Dirigente di Primo Livello presso il Laboratorio Chimico del Presidio Multizonale di Prevenzione di Genova, ASL3, Genova.
**02/05/1987-30/09/1988**: contrattista di ricerca, Istituto Nazionale per la Ricerca sul Cancro (IST) di Genova, responsabile scientifico Prof. Ranieri Cancedda.

**Attività scientifica**

**Pubblicazioni**
Autore ID: **7004138079**
ORCID: **0000-0001-9386-0445**

L'attività scientifica della Prof. Paola Fossa, documentata da 130 lavori pubblicati su riviste scientifiche a diffusione internazionale e da numerose comunicazioni a congressi nazionali ed internazionali, si è svolta prevalentemente presso il Dipartimento di Scienze Farmaceutiche dell'Università degli Studi di Genova ed è stata integrata da alcuni soggiorni di ricerca e studio presso laboratori italiani (Dipartimento Farmaco-Chimico, Università degli Studi di Bari) ed esteri (Dept. of Chemistry, Leiden University, Nederland e Institut fur Pharmazeutische Chemie, Dusseldorf University, Germany). La produzione scientifica di Paola Fossa, inizialmente rivolta alla sintesi di composti eterociclici con potenziale interesse farmaceutico, a partire dalla metà degli anni '90 si è orientata anche alla chimica computazionale, in particolare all'applicazione di strategie computazionali per la progettazione di sostanze farmacologicamente attive, allo studio delle interazioni a livello molecolare di ligandi con la loro controparte biologica, al calcolo di rapporti quantitativi struttura-attività (QSAR e 3D-QSAR) ed alla caratterizzazione di nuovi targets macromolecolari. Questo approccio di ricerca si è progressivamente consolidato portando all'acquisizione di specifiche competenze computazionali nell'ambito della drug discovery ed ha implicato una consistente interazione con ricercatori con competenze diverse dalla propria, accentuando quindi la capacità di lavorare all'interno di un team.
Nello sviluppo di queste ricerche, Paola Fossa ha stabilito fruttuose collaborazioni scientifiche con i seguenti gruppi di ricerca: Proff. A. Carotti e C. Altomare, Dipartimento di Farmacia- Scienze del Farmaco, Università degli Studi di Bari; Prof. L. Brasili e S. Franchini, Dipartimento Scienze della

Vita, Università degli Studi di Modena e Reggio Emilia; Dott. L. Milanesi, Istituto di Tecnologie Biomediche ITB, CNR, Segrate (MI); Prof. M. Rusnati, Dipartimento di Medicina Molecolare e Traslazionale, Università degli Studi di Brescia; Dott. N. Pedemonte, UOC Genetica Medica, Istituto Giannina Gaslini, Genova; Prof. G. Murineddu, Dipartimento di Chimica e Farmacia, Università degli Studi di Sassari; Prof. S. Rapposelli, Dipartimento di Farmacia, Università degli Studi di Pisa; Prof. R. Gainetdinov, Institute of Translational Biomedicine, Università degli Studi di San Pietroburgo, Russia. Paola Fossa inoltre collabora attivamente con gruppi di ricerca all'interno dell'Università degli Studi di Genova, Proff. E. Millo, E. Zocchi, P. Mandich, M. Grandis.

Paola Fossa ha partecipato all'organizzazione di alcuni meeting nell'ambito della chimica farmaceutica e della bioinformatica, è referee per numerose riviste scientifiche del settore chmico-farmaceutico (Journal of Medicinal Chemistry, European Journal Medicinal Chemistry, Bioorganic and Medicinal Chemistry, Molecules, Biomolecules, International Journal of Molecular Sciences per citare le principali).

**Elenco delle pubblicazioni**


1) Descalzi Cancedda F., Manduca P., Tacchetti C., **Fossa P.**, Quarto R., Cancedda R. Developmentally regulated synthesis of a low molecular weight protein (Ch 21) by differentiating chondrocytes. J. Cell Biol. 1988, 107, 2455-2463.

2) Manduca P., Descalzi Cancedda F., Tacchetti C., Quarto R., **Fossa P.**, Cancedda R. Synthesis and Secretion of Ch 21 Protein in embryonic chick skeletal tissues. Eur. J. Cell Biol. 1989, 50, 154-161.

3) Schenone P., **Fossa P.**, Menozzi G. Reaction of 2-Dimethylaminomethylene-1,3-diones with Dinucleophiles. X. Synthesis of 5-Substituted Ethyl or Methyl 4-Isoxazolecarboxylates and Methyl 4-(2,2-Dimethyl-1-oxopropyl)-5-isoxazolecarboxylate. J. Heterocyclic Chem. 1991, 28, 453-457.

4) **Fossa P.**, Menozzi G., Schenone P., Filippelli W., Russo S., Lucarelli C., Marmo E. 5-Substituted 4-Isoxazolecarboxamides with platelet antiaggregating and other activities. ll Farmaco 1991, 46, 789-802.

5) Mosti L., Sansebastiano L., **Fossa P.**, Schenone P., Mattioli F. 1-Phenyl-1H-indazole derivatives with analgesic and antiinflammatory activities. ll Farmaco 1992, 47, 357-365.

6) Mosti L., Menozzi G., **Fossa P.**, Schenone P., Lampa E., Parrillo C., D'Amico M., Rossi F. 4-Substituted 1-methyl-1H-indazoles with analgesic, antiinflammatory and antipyretic activities. ll Farmaco1992, 47, 567–84.

7) **Fossa P.**, Menozzi G., Schenone P., Mattioli F. 5-Substituted 4-Isoxazoleacetic acids with analgesic activity. ll Farmaco1994, 49, 41-44.

8) Iester M., **Fossa P.**, Menozzi G., Mosti L., Baccicchetti F., Marzano C., Simonato M. Synthesis and photobiological properties of 3-acylangelicins, 3-alkoxycarbonyl-angelicins and related derivatives. Farmaco 1995, 50, 669-678.

9) Dorigo P., Fraccarollo D., Santostasi G., Maragno I., Floreani M., Borea P. A., Mosti L., Sansebastiano L., **Fossa P.**, Orsini F., Benetollo F., Bombieri G. Synthesis and Cardiotonic Activity of Novel Pyrimidine Derivatives. Crystallographic and Quantum Chemical Studies. J. Med. Chem. 1996, 39, 3671-83.

10) Marzano C., Caffieri S., **Fossa P.**, Bordin F. Activity of 3-Carbethoxyangelicin Photolysis Products. J. Photochem. Photobiol. B:Biology 1997, 38, 189-195.

11) Boggia R., Forina M., **Fossa P.**, Mosti L. Chemometric Study and Validation Strategies in the Structure-Activity Relationships of New Cardiotonic Agents. Quant. Struct.-Act. Relat. 1997, 16, 201-213.

12) Mosti L., Boggia R., **Fossa P.** 2-Pyridone Derivatives as Inotropic Agents: Synthesis, Pharmacology and Molecular Modeling Study. Farmaco 1997, 52, 331-337.

13) Menozzi G., Mosti L., **Fossa P.**, Mattioli F., Ghia M. ω-Dialkylaminoalkil Ethers of Phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with Analgesic and Anti-inflammatory Activity. J. Heterocyclic Chem. 1997, 34, 963-968.
14) Floreani M., Borea P. A., Gessi S., Mosti L., **Fossa P.**, Dorigo P. A New Milrinone analog: Role of Binding to $A_1$ Adenosine Receptor in its Positive Inotropic Effect on Isolated Guinea Pig and Rat Atria. J Pharm. & Exp. Ther. 1997, 283, 541-547.
15) Forina M., Boggia R., Mosti L., **Fossa P.** Zupan's Descriptors in QSAR Applied to the Study of a New Class of Cardiotonic Agents. Farmaco 1997, 52, 411-419.
16) **Fossa P.**, Boggia R., Lo Presti E., Mosti L., Dorigo P., Floreani M. Inotropic Agents. Synthesis and Structure-Activity Relationships of New Milrinone Related cAMP PDE III Inhibitors. Farmaco 1997, 52, 523-30.
17) **Fossa P.**, Boggia R., Mosti L. Toward the identification of the cardiac cGMP inhibited-phosphodiesterase catalytic site. J. Comput.-Aided Mol. Des. 1998, 9, 361-72.
18) Altomare C., Cellamare S., Summo L., **Fossa P.**, Mosti L., Carotti A. Ionization Behaviour and Tautomeric-Dependent Lipophilicity of Pyridine-2 (1H)-one Cardiotonic Agents. Bioorg. Med. Chem. 2000, 8, 909-916.
19) Mosti L., Menozzi G., **Fossa P.**, Filippelli W., Gessi S., Rinaldi B., Falcone G. Synthesis and Preliminary Biological Evaluation of Novel N-Substituted 1-Amino-3-[1-methyl(phenyl)-1H-indazol-4-yloxy]-propan-2-ols Interesting as potential Antiarrhythmic, Local Anaesthetic and Analgesic Agents. Arzneim.-Forsch./Drug. Res. 2000, 50, 963-972.
20) **Fossa P.**, Menozzi G., Mosti L. An updated topographical model for phosphodiesterase 4 (PDE4) catalytic site. Quant. Struct.-Activity Rel. 2001, 20, 17-22.
21) Menozzi G., Mosti L., **Fossa P.**, Musiu C., Murgioni C., La Colla P. Synthesis and biological evaluation of azole derivatives, analogues of bifonazole, with a phenylisoxazol or phenylpyrimidinyl moiety. Farmaco 2001, 56, 633-640.
22) Schenone S., Bruno O., **Fossa P.**, Ranise A., Menozzi G., Mosti L., Bondavalli F., Martini C., Trincavelli L. Synthesis and Biological Data of 4-Amino-1-(2-chloro–2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic Acid Ethyl Esters, a New Series of $A_1$-Adenosine Receptor ($A_1$AR) Ligands. Bioorg. Med. Chem. Lett. 2001, 11, 2529-2531.
23) Betti L., Botta M., Corelli F., Floridi M., **Fossa P.**, Giannaccini G., Manetti F., Strappaghetti G., Corsano S. α1-Adrenoceptor Antagonists. Rational Design, Synthesis and Biological Evaluation of New Trazodone-like Compounds. Bioorg. Med. Chem. Lett. 2002, 12, 437-440.
24) **Fossa P.**, Mosti L., Menozzi G., Marzano C., Baccichetti F., Bordin F. Novel Angular Furo and Thieno-quinolinones: Synthesis and Preliminary Photobiological Studies. Bioorg. Med. Chem. 2002, 10, 743-751.
25) **Fossa P.**, Mosti L., Menozzi G., Manetti F., Dorigo P., Floreani M. 2-Substituted 5-acetyl-1,6-dihydro-6-oxo-3-pyridinecarboxylates: synthesis and cardiotonic activity. Med. Chem. Res. 2002, 11, 137-152.
26) **Fossa P.**, Giordanetto F., Menozzi G., Mosti L. Structural basis for selective PDE 3 inhibition: a docking study. Quant. Struct.-Act. Rel. 2002, 21, 267-675.
27) Bondavalli F., Botta M., Bruno O., Ciacci A., Corelli F., **Fossa P.**, Lucacchini A., Manetti F., Martini C., Menozzi G., Mosti L., Ranise A., Schenone S., Tafi A., Trincavelli M. L. Synthesis, Molecular Modeling Studies and Pharmacological Activity of Selective $A_1$ Receptor Antagonists. J. Med. Chem. 2002, 45, 4875-4887.
28) Floreani M., **Fossa P.**, Gessi S., Mosti L., Borea P. A., Dorigo P. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase. Naunyn-Schmiedebergs Arch. Pharmacol. 2003, 367, 109-118.
29) Giordanetto F., **Fossa P.**, Menozzi G., Schenone S., Bondavalli F., Ranise A., Mosti L. Exploring the molecular basis of selectivity in $A_1$ adenosine receptors agonists: a case study. J. Comput.-Aided Mol. Design 2003, 17, 39-51.

30) Giordanetto F., **Fossa P.**, Menozzi G., Mosti L. "In silico" rationalization of the structural and physicochemical requirements for photobiological activity in angelicine derivatives and their heteroanalogues. J. Comput.-Aided Mol. Des. 2003, 17, 53-64.
31) Menozzi G., Merello L., **Fossa P.**, Mosti L., Piana A., Mattioli F. 4-Substituted 1,5-diarylpyrazoles, analogues of celecoxib: synthesis and evaluation of biological properties. Farmaco 2003, 58, 795-808.
32) Ranise A., Spallarossa A., Bruno O., Schenone S., **Fossa P.**, Menozzi G., Bondavalli F., Mosti L., Capuano A., Mazzeo F., Falcone G., Filippelli W. Synthesis of N-substituted-N-acylthioureas of 4-substituted piperazines endowed with local anaesthetic, antihyperlipidemic, antiproliferative activities and antiarrythmic, analgesic, antiaggregating actions. Farmaco 2003, 58, 765-780.
33) **Fossa P.**, Menozzi G., Dorigo P., Floreani M., Mosti L. Synthesis and Pharmacological Characterisation of Functionalized 2-Pyridones Structurally Related to the Cardiotonic Agent Milrinone. Bioorg. Med. Chem. 2003, 11, 4749-4759.
34) Schenone S., Bruno O., Bondavalli F., Ranise A., Mosti L., Menozzi G., **Fossa P.**, Manetti F., Morbidelli L., Trincavelli L., Martini C., Lucacchini A. Synthesis of 1-(2-chloro-2-phenylethyl)-6-methylthio-1H-pyrazolo[3,4-d]pyrimidines 4-amino substituted and their biological evaluation. Eur. J. Med. Chem. 2004, 39, 153-160.
35) Carraro F., Pucci A., Naldini A., Schenone S., Bruno O., Ranise A., Bondavalli F., Brullo C., **Fossa P.**, Menozzi G., Mosti L., Manetti F., Botta M. Pyrazolo[3,4-d]pyrimidines Endowed with Antiproliferative Activity on Ductal Infiltrating Carcinoma Cells. J. Med. Chem. 2004, 47, 1595-1598.
36) Schenone S., Bruno O., Ranise A., Bondavalli F., Brullo C., **Fossa P.**, Mosti L., Menozzi G., Carraro F., Naldini A., Bernini C., Manetti F., Botta M. New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorg. Med. Chem. Lett. 2004, 14, 2511-2517.
37) Menozzi G., Merello L., **Fossa P.**, Schenone S., Ranise A., Mosti L., Bondavalli F., Loddo R., Murgioni C., Mascia V., La Colla P., Tamburini E. Synthesis, antimicrobial activity and molecular modeling studies of halogenated 4-[1H-imidazol-1-yl(phenyl)methyl]-1,5-diphenyl-1H-pyrazoles. Bioorg Med. Chem. 2004, 12, 5465-5483.
38) Schenone S., Bruno O., Bondavalli F., Ranise A., Mosti L., Menozzi G., **Fossa P.**, Donnini S., Santoro A., Ziche M., Manetti F., Botta M. Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. Eur. J. Med. Chem. 2004, 39, 939–946.
39) Tait A., Luppi A., Hatzelmann A., **Fossa P.**, Mosti L. Synthesis, Biological Evaluation and Molecular Modeling Studies on Benzothiadiazine Derivatives as PDE4 Selective Inhibitors. Bioorg. Med. Chem. 2005, 13, 1393-1402.
40) Ranise A., Spallarossa A., Cesarini S., Bondavalli F., Schenone S., Bruno O., Menozzi G., **Fossa P.**, Mosti L., La Colla M., Sanna G., Murreddu M., Collu G., Busonera B., Marongiu M. E., Pani A., La Colla P., Loddo R. Structure-Based Design, Parallel Synthesis, Structure-Activity Relationship, and Molecular Modeling Studies of Thiocarbamates, New Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitor Isosteres of Phenethylthiazolylthiourea Derivatives. J. Med. Chem. 2005, 48, 3858-3873.
41) **Fossa P.**, Pestarino M., Menozzi G., Mosti L., Schenone S., Ranise A., Bondavalli F., Trincavelli M. L., Lucacchini A., Martini C. New pyrazolo[3,4-b]pyridones as selective $A_1$ adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies. Org. Biomol. Chem. 2005, 3, 2262-2270.
42) de Candia M., **Fossa P.**, Cellamare S., Mosti L., Carotti A., Altomare C. Insights into Structure-Activity Relationships from Lipophilicity Profiles of Pyridin-2(1H)-one Analogs of the Cardiotonic Agent Milrinone. Eur. J. Pharm. Sci. 2005, 26, 78-86.
43) Manetti F., Schenone S., Bondavalli F., Brullo C., Bruno O., Ranise A., Mosti L., Menozzi G., **Fossa P.**, Trincavelli M. L., Martini C., Martinelli A., Tintori C., Botta M. Synthesis and 3D QSAR

of New Pyrazolo[3,4-*b*]pyridines: Potent and Selective Inhibitors of $A_1$ Adenosine Receptors. J. Med. Chem. 2005, 48, 7172-7185.
44) D'Ursi P., Salvi E., **Fossa P.**, Milanesi L., Rovida E. Modelling the interaction of steroid receptors with endocrine disrupting chemicals. BMC Bioinformatics 2005, 6(Suppl 4):S10. DOI: 10.1186/1471-2105-6-S4-S10.
45) **Fossa P.**, Mosti L., Bondavalli F., Schenone S., Ranise A., Casolino C., Forina M. Affinity Prediction on $A_1$ Adenosine Receptor Agonists: the Chemometric Approach. Bioorg. Med. Chem. 2006, 14, 1348-1363.
46) Carraro F., Naldini A., Pucci A., Locatelli G. A., Maga, G., Schenone S., Bruno O., Ranise A., Bondavalli F., Brullo C., **Fossa P.**, Menozzi G., Mosti L., Modugno M., Tintori C., Manetti F., Botta M. Pyrazolo[3,4-*d*]pyrimidines as Potent Antiproliferative and Proapoptotic Agents toward A431 and 8701-BC Cells in Culture via Inhibition of c-Src Phosphorylation, J. Med. Chem. 2006, 49, 1549-1561.
47) Roma G., Di Braccio M., Grossi G., Piras D., Leoncini G., Bruzzese D., Signorello M. G., **Fossa P.,** Mosti L. Synthesis and in Vitro Antiplatelet Activity of New 4-(1-Piperazinyl)coumarin Derivatives. Human Platelet Phosphodiesterase 3 Inhibitory Properties of the Two Most Effective Compounds Described and Molecular Modelling Study on Their Interactions with Phosphodiesterase 3A Catalytic Site. J. Med. Chem. 2007, 50, 2886-2895.
48) Ranise A., Cesarini S., Spallarossa A., Sancassan F., Bondavalli F., Schenone S., Bruno O., Menozzi G., **Fossa P.**, Mosti L.,Unprecedented One-pot Stereoselective Synthesis of Knoevenagel-type Derivatives of Potential Biological Interest Via in Situ Condensation of N-Methyleniminium Salts of Ethylenethiourea and Ethyleneurea with Active Methylene Reagents. Synthesis 2007, 16, 2495-2502.
49) Cesarini S., Spallarossa A., Ranise A., **Fossa P.**, La Colla P., Sanna G., Collu G., Loddo R., Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates. Bioorg. Med. Chem. 2008, 16, 4160-4172.
50) Menozzi G., **Fossa P.**, Cichero E., Spallarossa A., Ranise A., Mosti L., Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as $CB_1$ receptor antagonists, structurally related to rimonabant. Eur. J. Med. Chem. 2008, 43, 2627-2638.
51) Mosti L., **Fossa P.**, Menozzi G., Trincavelli L., Floreani M. Quinolinedione nucleus as a novel scaffold for $A_1$ and $A_{2A}$ adenosine receptor antagonists. Med. Chem. Res. 2008, 17, 587-603.
52) Cichero E., Menozzi G., Spallarossa A., Mosti L., **Fossa P.** Exploring the binding features of rimonabant analogues and acyclic $CB_1$ antagonists: docking studies and QSAR analysis. J. Mol. Model. 2008, 14, 1131-1145.
53) Cichero E., Cesarini S., **Fossa P.**, Spallarossa A., Mosti L., Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. Eur. J. Med. Chem. 2009, 44, 2059-2070.
54) Cichero E., Cesarini S., Spallarossa A., Mosti L., **Fossa P.**, Computational studies of the binding mode and 3D-QSAR analyses of symmetric formimidoester disulfides: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Mol. Model. 2009, 15, 357-367.
55) Cichero E., Casolino C., Menozzi G., Mosti L., **Fossa P.** Exploring the QSAR of pyrazolo[3,4-*b*]pyridine, pyrazolo[3,4-*b*]pyridone and pyrazolo[3,4-*b*]pyrimidine derivatives as antagonists for $A_1$ adenosine receptor. QSAR and Comb. Sci. 2009, 28, 426-435.
56) Cichero E, Cesarini S, Spallarossa A, Mosti L, **Fossa P.** Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analyses. J. Mol. Model. 2009, 15, 871-884.
57) Mandich P., **Fossa P.**, Capponi S., Geroldi S., Acquaviva M., Gulli R., Ciotti P., Manganelli F., Grandis M., Bellone E., Clinical features and molecular modelling of novel MPZ mutations in demyelinating and axonal neuropathies. Eur. J. Hum. Genet. 2009, 17, 1129-1134.

58) Cateni F., Zacchigna M., Pedemonte N., Galietta L.J., Mazzei M.T., **Fossa P.**, Giampieri M., Mazzei M. Synthesis of 4-thiophen-2'-yl-1,4-dihydropyridines as potentiators of the CFTR chloride channel. Bioorg. Med Chem. 2009, 17, 7894-7903.
59) Franchini S., Prandi A., Sorbi C., Tait A., Baraldi A., Angeli P., Buccioni M., Cilia A., Poggesi E., **Fossa P.**, Brasili L., Discovery of a new series of 5-HT1A receptor agonists. Bioorg. Med. Chem. Lett. 2010, 20, 2017-2020.
60) Cichero E., Cesarini S., Mosti L., **Fossa P.** CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective $CB_2$ receptor agonists. J. Mol. Model. 2010, 16, 677-691.
61) Cichero E., Cesarini S., Mosti L., **Fossa P.** CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective $CB_2$ receptor agonists. J. Mol. Model. 2010, 16, 1481-1498.
62) Franchini S., Prandi A., Baraldi A., Sorbi C., Tait A., Buccioni M., Marucci G., Cilia A., Pirona L., **Fossa P.**, Cichero E., Brasili L. 1,3-Dioxolane-based ligands incorporating a lactam or imide moiety: Structure-affinity/activity relationship at alpha(1)-adrenoceptor subtypes and at 5-HT(1A) receptors. Eur. J. Med. Chem. 2010, 45, 3740-3751.
63) Cichero E., Buffa L., **Fossa P.** 3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. J. Mol. Model. 2011, 17, 1537-1550.
64) Cichero E., Ligresti A., Allarà M., di Marzo V., Lazzati Z., D'Ursi P., Marabotti A., Milanesi L., Spallarossa A., Ranise A., **Fossa P**. Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the Human $CB_2$ Receptor, Eur. J. Med. Chem. 2011, 46, 4489-4505.
65) Capponi S., Geroldi A., **Fossa P.**, Grandis M., Ciotti P., Gulli R., Schenone A., Mandich P., Bellone E. HSPB1 and HSPB8 in inherited neuropathies: study of an Italian cohort of dHMN and CMT2 patients and design of a novel HSP27 3D homology model. J. Peripher. Nerv. Syst., 2011, 16, 287-294.
66) Origone P., Caponnetto C., Mantero V., Cichero E., **Fossa P.**, Geroldi A., Verdiani S., Bellone E., Mancardi G., Mandich P. Fast course ALS presenting with vocal cord paralysis: Clinical features, bioinformatic and modelling analysis of the novel SOD1 Gly147Ser mutation. Amyotroph. Lateral Scler. 2012, 13, 144-148.
67) Prandi A., Franchini S., Manasieva L., **Fossa P**, Cichero E., Marucci G., Buccioni M., Cilia A., Pirona L., Brasili L. Synthesis, Biological Evaluation and Docking Studies of tetrahydrofuran-cyclopentanone- and cyclopentanol-based ligands acting at alpha1- and 5-$HT_{1A}$ receptors. J. Med. Chem. 2012, 55, 23-36.
68) Brullo C., Rocca M., **Fossa P**., Cichero E., Barocelli E., Ballabeni V., Flammini L., Giorgio C., Saccani F., Bruno O., Synthesis of new 5,6-dihydrobenzo[*h*]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation, Biorg. Med. Chem. Lett. 2012, 22, 1125-1129.
69) Cichero E., **Fossa P**. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. J. Mol. Model. 2012, 18, 1573-1582.
70) Origone P., Caponetto C., Verdiani S., Mantero V., Cichero E., **Fossa P.**, Bellone E., Mancardi G.L., Mandich P. T137A variant is a pathogenetic *SOD1* mutation associated with a slowly progressive ALS phenotype. Amyotroph. Lateral Scler. 2012, 13, 398-399.
71) Basile A., Pascale M., Franceschinelli S., Nieddu E., Mazzei M. T., **Fossa P.**, Turco M. C., Mazzei M. Matrine modulates HSC70 levels and rescues DF508-CFTR, J. Cell. Physiol., 2012, 227, 3317-3323.
72) Cichero E., Bruno O., **Fossa P**. Docking-based CoMFA and CoMSIA analyses of tetrahydro-β-carboline derivatives as type-5 phosphodiesterase inhibitors. J. Enzyme Inhib. Med. Chem. 2012, 27, 730-743.

73) Cichero E., Basile A., Turco M. C., Mazzei M., **Fossa P.** Scouting new molecular targets for CFTR therapy: the HSC70/BAG-1 complex. A computational study. Med. Chem. Res. 2012, 21, 4430-3446.
74) Cichero E., Espinoza S., Gainetdinov R., Brasili L., **Fossa P.** Insights into the structure and pharmacology of the human trace amine-associated receptor 1 (hTAAR1): homology modeling and docking studies. Chem. Biol. Drug Des. 2013, 81, 509-516.
75) Di Braccio M., Grossi G., Signorello M.G., Leoncini G., Cichero E., **Fossa P.**, Alfei S., Damonte G. Synthesis, in vitro antiplatelet activity and molecular modelling studies of 10-substituted 2-(1-piperazinyl)pyrimido[1,2-a]benzimidazol-4(10H)-ones, Eur. J. Med. Chem. 2013, 62, 564-578.
76) Cichero E., D'Ursi P., Moscatelli M., Bruno O., Orro A., Rotolo C., Milanesi L., **Fossa P.** Homology modeling, docking studies and molecular dynamic simulations using GPU architecture to probe the type-11 Phosphodiesterase (PDE11) catalytic site: a computational approach for the rational design of selective inhibitors. Chem. Biol. Drug Des. 2013, 82, 718-731.
77) Cichero E., Espinoza S., Franchini S., Guariento S., Brasili L., Gainetdinov R.R., **Fossa P.** Further Insights Into the Pharmacology of the Human Trace Amine-Associated Receptors: Discovery of Novel Ligands for TAAR1 by a Virtual Screening Approach. Chem. Biol. Drug Des. 2014, 84, 712-20.
78) Brullo C., Massa M., Rocca M., Rotolo C., Guariento S., Rivera D., Ricciarelli R., Fedele E., **Fossa P**., Bruno O. Synthesis, Biological Evaluation, and Molecular Modeling of New 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-Dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) Related Phosphodiesterase 4D (PDE4D) Inhibitors. J. Med. Chem. 2014, 57, 7061-72.
79) Franchini S., Battisti U.M., Baraldi A., Prandi A., **Fossa P.**, Cichero E., Tait A., Sorbi C., Marucci G., Cilia A., Pirona L., Brasili L. Structure-affinity/activity relationships of 1,4-dioxa-spiro[4.5]decane based ligands at α1 and 5-$HT_{1A}$ receptors. Eur. J. Med. Chem. 2014, 87, 248-66.
80) **Fossa P.,** Cichero E., In silico evaluation of human small heat shock protein HSP27: Homology modelling, mutation analyses and docking studies, Bioorg. Med. Chem. 2015, 23, 3215-20.
81) Pesce E., Bellotti M., Liessi N., Guariento S., Cichero E., Galatini A., Salis A., Gianotti A., Pedemonte N., Zegarra-Moran O., **Fossa P.**, Galietta L.J., Millo E. Synthesis and investigation on the structure-activity relationships of aminoaryl thiazole derivatives to correct the chloride transport defect in cystic fibrosis, Eur. J. Med. Chem. 2015, 99, 14-35.
82) Chiellini G., Nesi G., Digiacomo M., Malvasi R., Espinoza S., Sabatini M., Frascarelli S., Laurino A., Cichero E., Macchia M., Gainetdinov R., **Fossa P.,** Raimondi L., Zucchi R., Rapposelli, S., Design, Synthesis and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists, J. Med. Chem. 2015, 58, 5096-107.
83) Pisciotta L., Vitali C., Favari E., **Fossa P**., Adorni M.P., Leone D., Artom N., Fresa R., Calabresi L., Calandra S., Bertolini S., A Complex Phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 Gene (apoA-I Guastalla), J. Clin. Lipidol. 2015, 9, 837-46.
84) Cichero E., Menozzi G., Guariento S., **Fossa P.** Ligand-based homology modelling of the human $CB_2$ receptor SR144528 antagonist binding site: a computational approach to explore the 1,5-diaryl pyrazole scaffold, MedChemComm. 2015, 6, 1978-1986.
85) Guariento S., Bruno O., **Fossa P.**, Cichero E., New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies, Mol. Divers. 2016, 20, 77-92.
86) Deiana V., Gómez-Cañas M., Pazos M.R., Fernández-Ruiz J., Asproni B., Cichero E., **Fossa P.**, Muñoz E., Deligia F., Murineddu G., García-Arencibia M., Pinna G.A. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential $CB_2$ receptor ligands with antagonist/inverse agonist properties. Eur. J. Med. Chem. 2016, 112, 66-80.
87) Franchini S., Battisti U.M., Prandi A., Tait A., Borsari C., Cichero E., **Fossa P.**, Cilia A., Prezzavento O., Ronsisvalle S., Aricò G., Parenti C., Brasili L. Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives. Eur. J. Med. Chem. 2016, 112, 1-19.

88) Cichero E., Brullo C., Bruno O., **Fossa P.,** Exhaustive 3D-QSAR analyses as a computational tool to explore the potency and selectivity profiles of thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDE7 inhibitors, RSC Adv., 2016, 6, 61088-61108.
89) Cichero E., Espinoza S., Tonelli M., Franchini S., Gerasimov A. S., Sorbi C., Gainetdinov R. R., Brasili L., **Fossa P.**, A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists, Med. Chem. Comm., 2016, 7, 353-364.
90) D'Ursi P., Guariento S., Trombetti G., Orro A., Cichero E., Milanesi L., **Fossa P.**, Bruno O. Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics. Mol. Inform. 2016; 35, 369-81.
91) Matveenko M., Cichero E., **Fossa P.**, Becker C.F. Impaired Chaperone Activity of Human Heat Shock Protein Hsp27 Site-Specifically Modified with Argpyrimidine. Angew. Chem. Int. Ed Engl. 2016, 55, 11397-402.
92) Brullo C., Ricciarelli R., Prickaerts J., Arancio O., Massa M., Rotolo C., Romussi A., Rebosio C., Marengo B., Pronzato M.A., van Hagen B.T., van Goethem N.P., D'Ursi P., Orro A., Milanesi L., Guariento S., Cichero E., **Fossa P**, Fedele E, Bruno O. New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment. Eur. J. Med. Chem. 2016, 124, 82-102.
93) Capponi S, Geuens T, Geroldi A, Origone P, Verdiani S, Cichero E, Adriaenssens E, De Winter V, Bandettini di Poggio M, Barberis M, Chiò A, **Fossa P.**, Mandich P, Bellone E, Timmerman V. Molecular Chaperones in the Pathogenesis of Amyotrophic Lateral Sclerosis: The Role of HSPB1. Hum. Mutat. 2016, 37, 1202-1208.
94) Dore A., Asproni B., Scampuddu A., Gessi S., Murineddu G., Cichero E., **Fossa P.**, Merighi S., Bencivenni S., Pinna G.A. Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as $CB_2$ receptor antagonists/inverse agonists. Bioorg. Med. Chem. 2016, 24, 5291-5301.
95) Chiellini G., Nesi G., Sestito S., Chiarugi S., Runfola M., Espinoza S., Sabatini M., Bellusci L., Laurino A., Cichero E., Gainetdinov R. R., **Fossa P.**, Raimondi L., Zucchi R., Rapposelli S. Hit-to-lead optimization of mouse Trace Amine Associated Receptor 1 (mTAAR1) agonists with a diphenylmethane-scaffold: Design, Synthesis, and biological study. J. Med. Chem. 2016, 59, 9825-9836.
96) Franchini S., Manasieva L., Sorbi C., Battisti U.M., **Fossa P.**, Cichero E., Denora N., Iacobazzi R.M., Cilia A., Pirona L., Ronsisvalle S., Aricò G., Brasili L. Synthesis, Biological Evaluation and Molecular Modelling of 1-oxa-4-thiaspiro- and 1,4-dithiaspiro[4.5]decane derivatives as potent and selective 5-$HT_{1A}$ Receptor Agonists. Eur. J. Med. Chem. 2017, 125, 435-452.
97) Guariento S., Karawajczyk A. Bull J. A., Marchini G., Bielska M., Iwanowa X., Bruno O., **Fossa P.,** Giordanetto F. Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors. Bioorg. Med. Chem. Lett. 2017, 27 24–29.
98) Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, **Fossa P**, Pinna GA, Jagerovic N, Fernández-Ruiz J, Murineddu G. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. Eur. J. Med. Chem. 2017, 127, 398-412.
99) Guariento S., Franchini S., Tonelli M., **Fossa P.**, Sorbi C., Cichero E., Brasili, L. Exhaustive CoMFA and CoMSIA analyses around different chemical entities: a ligand-based study exploring the affinity and selectivity profiles of 5-$HT_{1A}$ ligands. J. Enzyme Inhib. Med. Chem. J. Enzyme Inhib. Med. Chem. 2017, 32, 214-230.
100) Boido V., Ercoli M., Tonelli M., Novelli F., Tasso B., Sparatore F., Cichero E., **Fossa P**, Dorigo P., Froldi G. New arylsparteine derivatives as positive inotropic drugs. J. Enzyme Inhib. Med. Chem. 2017, 32, 588-599.
101) Cichero E., Tonelli M., Novelli F., Tasso B., Delogu I., Loddo R., Bruno O., **Fossa, P.** Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV

infection: a computational study exploring the potency and cytotoxicity profiles. J. Enzyme Inhib. Med. Chem. 2017, 32, 375-402.
102) Franchini S., Sorbi C., Battisti U. M., Tait A., Bancheva L. I., Cichero E., **Fossa P**., Cilia A., Prezzavento O., Ronsisvalle S., Aricò G., Benassi L., Vaschieri C., Azzoni P., Magnoni C. Brasili L., Structure-Activity Relationship within a new series at sigma2R ligands: identification of a novel σ2 receptor agonist (BS148) with selective toxicity against metastatic melanoma. ChemMedChem 2017, 12, 1893-1905.
103) Asproni B., Manca I., Pinna G., Cichero E.,**Fossa P.**, Murineddu G., Lazzari P. Loriga G., Pinna G.A. Novel pyrrolocycloalkylpyrazole analogues as $CB_1$ ligands. Chem. Biol. Drug Des. 2018, 91, 181-193.
104) Di Rocco G., Martinelli I., Pacifico S., Guerrini R., Cichero E., **Fossa P.**, Franchini S., Cardarelli S., Giorgi M., Ponterini G., FRET-based detection of protein-ligand engagement: the case of Phosphodiesterase5. J. Pharm. Biomed. Anal. 2018, 149, 335-342.
105) Murineddu G., Deligia F., G. Ragusa, García-Toscano L., Gómez-Cañas M., Asproni B., Satta V., Cichero E., Pazos R., **Fossa P.**, Loriga G., Fernández-Ruiz J., Pinna G. A. Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as $CB_1$ receptor ligand antagonists. Bioorg. Med. Chem. 2018, 26, 295-307.
106) Liessi N., Cichero E., Pesce E., Arkel M., Salis A., Tomati V., Paccagnella M., Damonte G., Tasso B., Pedemonte N., Galietta L. J. V., **Fossa P.**, Millo E.. Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools. Eur. J. Med. Chem. 2018, 144, 179-200.
107) Rusnati M., Sala D., Orro A., Bugatti A., Trombetti G., Cichero E., Urbinati C., Di Somma M., Millo E., Galietta L. J. V., Milanesi L., **Fossa P.** , D'Ursi P. Speeding up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: an Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance. Molecules 2018, 23, pii: E120.
108) Cichero E., Fresia C., Guida L., Booz V., Millo E., Scotti C., Iamele L., de Jonge H., Galante D., De Flora A., Sturla L., Vigliarolo T., Zocchi E., **Fossa P.** Identification of a high affinity binding site for abscisic acid on human lanthionine synthetase component C-like protein 2. Int. J. Biochem. Cell Biol. 2018, 97, 52-61.
109) Franchini S., Bencheva L., Battisti U., Sorbi C., Tait A., **Fossa, P**., Cichero, E., Ronsisvalle, S., Arico' G., Denora N., Iacobazzi R., Cilia A., Pirona L., Brasili, L. Synthesis and biological evaluation of 1,3-dioxolane-based 5-$HT_{1A}$ receptor agonists for CNS disorders and neuropathic pain, Future Med. Chem. 2018, 10, 2137-2154.
110) Tonelli M., Cichero E., Mahmoud A.M., Rabbito A., Tasso B., **Fossa P.**, Ligresti A. Exploring the effectiveness of novel benzimidazoles as $CB_2$ ligands: synthesis, biological evaluation, molecular docking studies and ADMET prediction, MedChemComm. 2018, 9, 2045-2054.
111) Gemelli C., Prada V., Fiorillo C., Fabbri S., Maggi L., Geroldi A., Gibertini S., Mandich P., Trevisan L., **Fossa P.**, Tagliafico A. S., Schenone A., Grandis M. A novel mutation in the N-terminal acting-binding domain of Filamin C protein causing a distal myofibrillar myopathy. J. Neurol. Sci. 2019, 398, 75-78.
112) D'Ursi P., Uggeri M., Urbinati C., Millo E., Paiardi G., Milanesi L., Ford R. C., Clews J., Meng X., Bergese P., Ridolfi A., Pedemonte N., **Fossa P.**, Orro A., Rusnati M. Exploitation of a novel biosensor based on the full-length human F508del-CFTR with computational study, biochemical and biological assays for the characterization of a new Lumacaftor/Tezacaftor analogue. Sens. Actuators B. Chem. 2019, 301, 127131.
113) Rusnati M., D'Ursi P., Pedemonte N., Urbinati C., Ford R. C., Cichero E., Uggeri M., Orro A., **Fossa P.** Recent strategic advances in CFTR drug discovery: an overview. Int. J. Mol. Sci. **2020**, 21, 2407.
114) Geroldi A., Prada V., Veneri F., Trevisan L., Origone P., Grandis M., Schenone A., Gemelli C., Lanteri P., **Fossa P.**, Mandich P., Bellone E. Early onset demyelinating Charcot-Marie-Tooth disease

caused by a novel in-frame isoleucine deletion in peripheral myelin protein 2. J. Peripher. Nerv. Syst. 2020, 25:102-106.
115) Gütschow M., Eynde J.J.V., Jampilek J., Kang C., Mangoni A.A., Fossa P., Karaman R., Trabocchi A., Scott P.J.H., Reynisson J., Rapposelli S., Galdiero S., Winum J.Y., Brullo C., Prokai-Tatrai K., Sharma A.K., Schapira M., Azuma Y.T., Cerchia L., Spetea M., Torri G., Collina S., Geronikaki A., García-Sosa A.T., Vasconcelos M.H., Sousa M.E., Kosalec I., Tuccinardi T., Duarte I.F., Salvador J.A.R., Bertinaria M., Pellecchia M., Amato J., Rastelli G., Gomes P.A.C., Guedes R.C., Sabatier J.M., Estévez-Braun A., Pagano B., Mangani S., Ragno R., Kokotos G., Brindisi M, González F.V., Borges F., Miloso M., Rautio J., Muñoz-Torrero D. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7. Molecules. 2020, 25:2968.
116) Saveri P., De Luca M., Nisi V., Pisciotta C., Romano R., Piscosquito G., Reilly M.M., Polke J.M., Cavallaro T., Fabrizi G.M., **Fossa P.**, Cichero E., Lombardi R., Lauria G., Magri S., Taroni F., Pareyson D., Bucci C. Charcot-Marie-Tooth Type 2B: A New Phenotype Associated with a Novel *RAB7A* Mutation and Inhibited EGFR Degradation. Cells. 2020, 9, pii: E1028.
117) Righetti G., Casale M., Tonelli M., Liessi N., **Fossa P.**, Pedemonte N., Millo E., Cichero E. New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach. Pharmaceuticals 2020, 13, 445, 1-28.
118) Linciano P., Sorbi C., Comitato A., Lesniak A., Bujalska-Zadrożny M., Pawłowska A., Bielenica A., Orzelska-Górka .J, Kędzierska E., Biała G., Ronsisvalle S., Limoncella S., Casarini L., Cichero E., **Fossa P.**, Satała G., Bojarski A.J., Brasili L., Bardoni R., Franchini S. Identification of a Potent and Selective 5-$HT_{1A}$ Receptor Agonist with *In Vitro* and *In Vivo* Antinociceptive Activity. ACS Chem. Neurosci. 2020, 11, 4111-4127.
119) Righetti G., Tonelli M., **Fossa P.**, Cichero E. Exploring the selectivity profile of sigma receptor ligands by molecular docking and pharmacophore analyses. Med Chem. 2020.
120) Righetti G., Casale M., Liessi N., Tasso B., Salis A., Tonelli M., Millo E., Pedemonte N., **Fossa P.**, Cichero E. Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR correctors. Int. J. Mol. Sci. 2020, 21, 8084, 1-27.
121) Orro A., Uggeri M., Rusnati M., Urbinati C., Pedemonte N., Pesce E., Moscatelli M., Padoan R., Cichero E., **Fossa P.**, D'Ursi P. In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library. Eur. J. Med. Chem. 2021, 213, 113186.
122) Iobbi V., Brun P., Bernabé G, Dougué Kentsop R.A., Donadio G., Ruffoni B., **Fossa P.**, Bisio A., De Tommasi N. Labdane Diterpenoids from *Salvia tingitana* Etl. Synergize with Clindamycin against Methicillin-Resistant *Staphylococcus aureus*. Molecules. 2021; 26, 6681.
123) Rondina A., **Fossa P.**, Orro A., Milanesi L., De Palma A., Perico D., Mauri P.L., D'Ursi P. A Boron Delivery Antibody (BDA) with boronated specific residues: new perspectives in Boron Neutron Capture Therapy. *Cells* 2021; *10*, 3225.
124) Cichero E., Calautti A., Francesconi V., Tonelli M., Schenone S., **Fossa P**. Probing in silico the benzimidazole privileged scaffold for the development of drug-like anti-RSV agents. Pharmaceutics 2021, 14, 1307.
125) Iobbi V., Lanteri A.P., Minuto A., Santoro V., Ferrea G., **Fossa P.**, Bisio A. Autoxidation Products of the Methanolic Extract of the Leaves of Combretum micranthum Exert Antiviral Activity against Tomato Brown Rugose Fruit Virus (ToBRFV). Molecules. 2022; 27, 760.
126) D'Ursi P, **Fossa P.** An Update on CFTR Drug Discovery: Opportunities and Challenges. Biomolecules. 2022;12(6):792.
127) **Fossa P.**, Uggeri M., Orro A., Urbinati C., Rondina A., Milanesi M., Pedemonte N., Pesce E., Padoan R., Ford R.C., Meng X., Rusnati M., D'Ursi P. Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing. Int J Mol Sci. 2022;23(20):12274.
128) Iobbi V., Santoro V., Maggi N., Giacomini M., Lanteri A.P., Minuto G., Minuto A., **Fossa P.**, De Tommasi N., Bisio A., Drava G., Characterization of sulfur compounds and antiviral activity

against Tomato brown rugose fruit virus (ToBRFV) of Italian “Vessalico” garlic compared to other cultivars and landrace, LWT 2023, 174, 114411.
129) Asproni B., Catto M., Loriga G., Murineddu G., Corona P., Purgatorio R., Cichero E., **Fossa P.**, Scarano N., Martínez A. L., Brea J., Pinna G. A., Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT6 receptor interaction, Bioorg. Med. Chem. 2023, 84, 117256.
130) Scarano N., Abbotto E., Musumeci F., Salis A., Brullo C., **Fossa P.**, Schenone S., Bruzzone S., Cichero E. Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors. Int J Mol Sci. 2023; 24, 9363.